Trials / Terminated
TerminatedNCT03805841
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Rain Oncology Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open-label, Phase 2, single treatment arm, 3 cohorts
Conditions
- NSCLC, Stage IV
- NSCLC Stage IIIB
- NSCLC, Stage IIIC
- NSCLC, Recurrent
- EGFR Exon 20 Insertion Mutation
- HER2-activating Mutation
- ERBB Fusion
- NRG1 Fusion
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tarloxotinib bromide | weekly intravenous infusion |
Timeline
- Start date
- 2019-03-13
- Primary completion
- 2021-04-09
- Completion
- 2021-04-23
- First posted
- 2019-01-16
- Last updated
- 2023-06-28
- Results posted
- 2023-06-28
Locations
14 sites across 3 countries: United States, Canada, Hong Kong
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03805841. Inclusion in this directory is not an endorsement.